Abstract: This invention discloses the use of muscarinic anti-cholinergic agents for reducing or preventing the toxic or lethal effects (such as seizures and brain damage) caused by cholinergic neurotoxins. The parent application disclosed that certain muscarinic anti-cholinergics classified as aryl-cycloalkyl-alkanolamines are effective in reducing or preventing the neurotoxicity of soman, a powerful nerve gas. This invention extends that discovery and identifies other muscarinic anti-cholinergic agents, including scopolamine, benactyzine, and benztropine, as highly effective and useful agents to protect against two major classes of cholinergic neurotoxins (acetylcholine receptor agonists, and cholinesterase inhibitors). Analogs of those compounds may also be effective in protecting against cholinergic neurotoxicity, as can be determined through routine screening tests using rats.

Abstract: A compound and method are disclosed for reducing neurotoxic effects (such as seizures and brain damage) caused by cholinergic agents such as soman (a nerve gas) and pilocarpine (a convulsant drug used to study the mechanisms of epilepsy). Effective treatment can be provided by administering an aryl-cycloalkylalkanolamine substance having the general formula: ##STR1## The compoudns procyclidine, biperiden, and trihexyphenidyl fall within this class of compounds. Although not previously recognized to be effective against soman or other cholinergic neurotoxins, all three representative compounds have been discovered to be highly effective against all cholinergic neurotoxins tested to data, even when administered after actual seizures begin.

Abstract: Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an aryl-cycloalkyl-alkanolamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites.

Abstract: Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an alkylated bicycloalkaneamine compound as an antagonist to inhibit excitotoxic actions at major neuronal exzcitatory amino acid receptor sites.

Abstract: Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of a phenothiazinealkaneamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of most interest are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is hydrido; wherein each of R.sup.3 and R.sup.4 is independently selected from hydrido, methyl and ethyl; wherein each of R.sup.5 and R.sup.6 is independently selected from methyl, ethyl and n-propyl; wherein X is sulfur; wherein m is zero; and wherein n is two.

Abstract: Methods and compositions are described for treatment to control brain damage associated with anoxia or ischemia which typically follows stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an alkenyl-substituted or alkynyl-substituted thiobarbiturate characterized in having broad-spectrum activity as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites.